.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Julphar
Medtronic
Boehringer Ingelheim
US Army
AstraZeneca
Accenture
Citi
UBS

Generated: November 24, 2017

DrugPatentWatch Database Preview

LEXISCAN Drug Profile

« Back to Dashboard

Which patents cover Lexiscan, and when can generic versions of Lexiscan launch?

Lexiscan is a drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-four patent family members in twenty-six countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in LEXISCAN is regadenoson. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the regadenoson profile page.

Summary for LEXISCAN

Pharmacology for LEXISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LEXISCAN

Drugname Dosage Strength RLD Submissiondate
regadenosonInjection0.08 mg/mL, 5 mL vialLexiscan4/10/2012

Non-Orange Book Patents for Tradename: LEXISCAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,956,179Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
8,906,878Myocardial perfusion imaging methods and compositions► Subscribe
8,278,435N-pyrazole A2A receptor agonists► Subscribe
8,071,566Methods of coronary imaging► Subscribe
8,268,988Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
9,163,057Methods of myocardial perfusion imaging► Subscribe
8,524,883Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide► Subscribe
7,671,192Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs► Subscribe
8,569,260N-pyrazole A.sub.2A receptor agonists► Subscribe
7,732,595Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LEXISCAN

Country Document Number Estimated Expiration
MexicoPA05001123► Subscribe
Luxembourg91785► Subscribe
Norway2011002► Subscribe
South Korea20130130868► Subscribe
World Intellectual Property Organization (WIPO)0078779► Subscribe
Australia2003259264► Subscribe
New Zealand570239► Subscribe
European Patent Office1989214► Subscribe
Canada2377746► Subscribe
New Zealand516334► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LEXISCAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/005United Kingdom► SubscribePRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
2/2011Austria► SubscribePRODUCT NAME: REGADENOSON UND DESSEN SALZE
2011000010Germany► SubscribePRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
785Luxembourg► Subscribe91785, EXPIRES: 20250621
90003-2.LSweden► SubscribePRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
2011Austria► SubscribePRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
C0004France► SubscribePRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2011 00005Denmark► Subscribe
2Finland► Subscribe
C004/2011Ireland► SubscribeSPC004/2011: 20110719, EXPIRES: 20250620
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Moodys
McKesson
Federal Trade Commission
Chubb
Julphar
US Army
Cipla
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot